RxDoctor Payments Data

Rachel Roth, PA

Physician Assistant · Newport Beach, CANPI 1609547926

Payments from drug & device makers

$1,821in general payments, 2019–2025

Across 79 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$543
  • Lilly USA, LLC$258
  • GSK$162
  • AstraZeneca$133
  • Eisai Inc.$105
  • Halozyme Inc$68
  • plus $553 from 15 others

What the payments were for

  • Consulting fees$1056%
  • Food & beverage$1,71694%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,821 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$47,287
Medicare patients
259
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$73,838
MounjaroTirzepatide46$46,109
EliquisApixaban33$33,997
JanuviaSitagliptin Phosphate27$33,540
JardianceEmpagliflozin26$30,299
FarxigaDapagliflozin Propanediol14$17,397
RybelsusSemaglutide16$15,235
TrulicityDulaglutide14$13,462
MyrbetriqMirabegron17$11,536
Combivent RespimatIpratropium/Albuterol Sulfate16$7,193
Breo ElliptaFluticasone/Vilanterol16$6,145
Repatha SureclickEvolocumab11$5,849
Alendronate Sodium41$3,714
Dantrolene Sodium13$3,131
SymbicortBudesonide/Formoterol Fumarate13$3,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$67$89,07390 claims
Lilly USA, LLCMounjaro, Trulicity$258$59,57160 claims
PfizerEliquis$18$33,99733 claims
AstraZenecaFarxiga, Symbicort$133$20,46727 claims
GSKBreo Ellipta$162$6,14516 claims
AbbVieSynthroid$543$2,62837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →